Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin added to standard Helicobacter pylori eradication therapy
IRCT20260929071236N1Phase 3Not yet recruiting
- Sponsor
- Ardabil University of Medical Sciences
- Start
- Nov 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Helicobacter pylori infection comparing Standard eradication regimen + rosuvastatin with Standard eradication regimen + placebo (2 arms). Primary endpoint: Helicobacter pylori eradication. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
rosuvastatin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20260929071236N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260929071236N1.